Clinical Trial Update: Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trials evaluated the safety, tolerability, immunogenicity, and preliminary efficacy of the NDV-3A vaccine to prevent recurrent vulvovaginal c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis

Drugs mentioned

• NDV-3A vaccine (NDV-3A)

Snippet

Sponsor: NovaDigm Therapeutics, Inc. | Conditions: Vulvovaginal Candidiasis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-06-20